SG Americas Securities LLC Buys 8,314 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)

SG Americas Securities LLC lifted its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) by 25.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,779 shares of the company’s stock after purchasing an additional 8,314 shares during the quarter. SG Americas Securities LLC’s holdings in Sutro Biopharma were worth $175,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Sutro Biopharma by 19.6% in the 2nd quarter. BlackRock Inc. now owns 6,005,557 shares of the company’s stock worth $27,926,000 after purchasing an additional 984,734 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Sutro Biopharma by 1,275.7% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,105,132 shares of the company’s stock worth $10,775,000 after purchasing an additional 2,879,412 shares in the last quarter. State Street Corp boosted its position in shares of Sutro Biopharma by 57.9% in the 1st quarter. State Street Corp now owns 2,922,712 shares of the company’s stock worth $13,503,000 after purchasing an additional 1,071,427 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Sutro Biopharma by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,868,762 shares of the company’s stock worth $9,955,000 after purchasing an additional 38,854 shares in the last quarter. Finally, Candriam S.C.A. boosted its position in shares of Sutro Biopharma by 135.8% in the 1st quarter. Candriam S.C.A. now owns 1,860,775 shares of the company’s stock worth $7,913,000 after purchasing an additional 1,071,591 shares in the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Insider Buying and Selling at Sutro Biopharma

In other Sutro Biopharma news, insider Nicki Vasquez sold 12,185 shares of Sutro Biopharma stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $5.00, for a total transaction of $60,925.00. Following the completion of the transaction, the insider now owns 12,803 shares in the company, valued at approximately $64,015. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ STRO opened at $4.14 on Monday. The stock has a 50-day simple moving average of $4.55 and a two-hundred day simple moving average of $3.86. The firm has a market capitalization of $258.50 million, a P/E ratio of -2.33 and a beta of 0.95. Sutro Biopharma, Inc. has a fifty-two week low of $2.01 and a fifty-two week high of $6.13.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on STRO. Piper Sandler restated an “overweight” rating and issued a $11.00 target price (down previously from $12.00) on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Truist Financial reduced their target price on Sutro Biopharma from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. HC Wainwright reduced their target price on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, March 26th. JMP Securities restated a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Finally, Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.57.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.